CCL20及其受体CCR6在COPD气道内及外周血的变化及意义  

The changes of CCL20 and its receptor CCR6 in COPD airway and peripheral blood and the therapeutic effect of CCL20 antibodies

作　　者：顾延会[1] 符丹丹[1] 饶习敏[1] 欧阳瑶[1] 

机构地区：[1]遵义医学院附属医院呼吸内科,贵州遵义563099

出　　处：《遵义医学院学报》2016年第3期266-269,共4页Journal of Zunyi Medical University

基　　金：国家自然科学基金资助项目(NO:81460008);贵州省科学技术基金资助项目(NO:黔科合J字LKZ(2012)08);贵州省省长基金资助项目(NO:黔科合SY字[2009]3053)

摘　　要：目的研究CCL20、CCR6在COPD大鼠支气管肺泡灌洗液(BALF)及外周血中的含量及CCL20抗体治疗后的变化,以了解CCL20/CCR6趋化轴在COPD发病过程中的可能作用机制及CCL20抗体的治疗作用。方法 30只Wistar大鼠随机分为正常组、COPD组及CCL20治疗组,每组10只,采用烟熏4周及气道内注入脂多糖(LPS)2次的方法制备COPD组模型,CCL20治疗组模型于造模前第1天腹腔内注入CCL20抗体,余处理同COPD组。3组大鼠均于4周后处死取其肺组织行病理HE染色,同时采用ELISA方法测定BALF及外周血中CCL20、CCR6的含量。结果 COPD组大鼠肺组织病理显示符合人类COPD特征性病理改变,CCL20治疗组肺组织病理显示其病变性质较COPD组减轻。CCL20治疗组大鼠BALF中CCL20及CCR6含量均高于正常对照组,差异有统计学意义(P<0.05),但低于COPD组,差异均有统计学意义(P<0.05)。CCL20治疗组大鼠外周血中CCL20的含量高于正常对照组,差异有统计学意义(P<0.05),但与COPD组相比差异无统计学意义;外周血中CCR6的含量在3组差异无统计学意义。结论 CCL20及其受体CCR6可能参与COPD发病及进展过程,CCL20抗体可影响CCL20及CCR6在气道内的变化,可改善COPD大鼠一般状态及病理损伤进展。Objective To study the contents of CCL20 and CCR6 in COPD rats broncho-alveolar lavage fluid（BALF） and peripheral blood,and the therapeutic effect of CCL20 antibodies,in order to understand the possible mechanism of CCL20/CCR6 chemotaxis on the pathogenesis of COPD.Methods 30 Wistar rats were randomly divided into normal group（n = 10）,COPD group（n = 10） and treatment with CCL20 antibody group（n= 10）.The rats of COPD group were established via cigarette inhalation for 4 weeks and intratracheal lipopolysaccharide（LPS） solution twice totally,and there were intraperitoneal injection of CCL20 antibody in the treatment of CCL20 groups on the first day.The pathomorphology of rats＇ lung and bronchiole were investigated by HE staining after 4 weeks,while the contents of CCL20 and CCR6 were analyzed with ELISA in the BALF and peripheral blood.Results The changes of pathology of the COPD group of rat lung tissue were the same as those of COPD patients,and the treatment of CCL20 antibody reduced lesions in the COPD group.The contents of CCL20 and CCR6 in BALF of CCL20 antibody group were significantly increased compared with the normal control group（P〈0.05）,but were significantly decreased compared with the COPD group,there was a difference statistically significant（P〈0.05）.The contents of CCL20 in the peripheral blood CCL20 antibody group were significantly increased compared with the normal control group,but there was no difference compared with the COPD group;the contents of CCR6 in peripheral blood in three groups had little changes,there were no differences.Conclusion CCL20 and its receptor CCR6 may participate in COPD pathogenesis process,CCL20 antibody can change the contents of CCL20 and CCR6 in the airway,and can improve the general status and pathologic progression of COPD rats.

关 键 词：慢性阻塞性肺疾病 WISTAR大鼠 CCL20 CCR6 

分 类 号：R563.3[医药卫生—呼吸系统]